
In a session at ACAAI’s Annual Scientific Meeting, David R. Weldon, MD, FACAAI, FAAAI, demonstrates punch biopsies for allergists and discusses the importance of knowing when to collaborate with dermatologists.

In a session at ACAAI’s Annual Scientific Meeting, David R. Weldon, MD, FACAAI, FAAAI, demonstrates punch biopsies for allergists and discusses the importance of knowing when to collaborate with dermatologists.

Patch testing can prove very useful in patients with suspected sensitization to a variety of allergens contained in personal care products and orthopedic implants.

Helen Brough, MA, MSc, PhD, MBBS, FAAAAI, FRCPCH, discusses the role of AD skin in infants and emollient application for preventing food allergy.

In this video interview, Mark Serota, MD, highlights the key talking points from his session at the 2021 ACAAI annual scientific meeting.

Involving patients with atopic dermatitis in decisions about developing their treatment plan can lead to improved treatment outcomes and higher satisfaction, the American College of Allergy, Asthma & Immunology (ACAAI) medical director said in a luncheon presentation at the college’s 2021 Annual Scientific Symposium.

In this video interview, Jeff Yu, MD, highlights key talking points from his session on regional dermatitis and rash from the American College of Allergy, Asthma & Immunology annual scientific meeting.

A study presented at the 2021 ACAAI annual scientific meeting shows data demonstrating severe atopic dermatitis in pediatric patients is better controlled through multidisciplinary clinics.

There are several fine nuances and differences in the presentation of atopic dermatitis in patients with skin of color that differ from the presentation seen in patients with lighter skin types. As such, clinicians should be aware of these differences to improve the treatment and management of AD in patients with skin of color.

Several doctors were recognized at the American College of Allergy, Asthma, & Immunology annual scientific meeting held November 4 to 8 in New Orleans, Louisiana.

Incyte announced that ruxolitinib cream has received validation for its European marketing authorization application from the European Medicines Agency.

In this video interview, Jeff Yu, MD, talks about what he's looking forward to at the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.

Sessions with a laser focus on dermatologic issues ranging from new JAK inhibitors to disparities in atopic dermatitis anchor the opening day of the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.

In this video, Ama Alexis, MD, tells us what we have to look forward to at the ACAAI conference this week.

Jonathan M. Spergel, MD, PhD, FACAAI discusses what there is to look forward to at the ACAAI conference and what he's highlighting at the event.

In this video, we talk to Michael Gold, MD, about the 11th annual New Frontiers in Cosmetic Medicine and Medical Dermatology symposium. He tells us the highlights of the conference and what makes it stands out from the rest.

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

Botulinum type A injections are widely used across the dermatology and aesthetic medicine specialties. At the Fall Clinical Dermatology Conference 2021, Mark S Nestor, MD, PhD, highlights how to optimize the neurotoxin to improve patient care.

Racial disparities in antibiotic prescription also influence treatment decisions.

People are born with sterile skin and then gain microbiota throughout their life. Lawrence J. Green, MD, FAAD, explains how this affects the skin barrier and ultimately plays a role in atopic dermatitis at the 2021 Fall Clinical Dermatology Conference.

ICYMI, some of this week’s featured content includes an exclusive interview about eczema, and articles on a new tralokinumab data, apremilast as a combination treatment, and more.

In a video onsite at Fall Clinical Dermatology Conference, Darrell S. Rigel, MD, MS, highlights, in his own words, the potential of GEP as an adjunct to biopsy in melanoma detection.

Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.

LEO Pharma releases the 16-week data regarding tralokinumab (Adtralza; LEO Pharma) as a treatment for adolescent patients aged 12 to 17 years.

Cantharidin 0.7% could be an emerging standard for molluscum treatment.

How can GEP be applied to melanoma diagnosis and treatment? Darrel Rigel, MD, MS, answers these questions and dives into the data at Fall Clinical Dermatology Conference 2021.

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

Click here to answer this week's poll.

Which is more worrisome, neonatal or infantile acne? An expert answered this question and more during Maui Derm NP+PA Fall 2021’s update on acne and rosacea.

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.